PE20141067A1 - Compuestos para el tratamiento de la adiccion - Google Patents
Compuestos para el tratamiento de la adiccionInfo
- Publication number
- PE20141067A1 PE20141067A1 PE2013002811A PE2013002811A PE20141067A1 PE 20141067 A1 PE20141067 A1 PE 20141067A1 PE 2013002811 A PE2013002811 A PE 2013002811A PE 2013002811 A PE2013002811 A PE 2013002811A PE 20141067 A1 PE20141067 A1 PE 20141067A1
- Authority
- PE
- Peru
- Prior art keywords
- optionally substituted
- compounds
- alkyl
- treatment
- benzamide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
Abstract
SE REFIERE A COMPUESTOS DE FORMULA (I) DONDE R1 ES H, ALQUILO C1-6 OPCIONALMENTE SUSTITUIDO, CH2OH, ENTRE OTROS; R2 ES H, ALQUILO C1-6 OPCIONALMENTE SUSTITUIDO, CICLOALQUILO O HALO; R3, R4, R5, R6, R9, R10, R11, R12, R13 SON INDEPENDIENTEMENTE H, HIDROXILO, ALQUILO OPCIONALMENTE SUSTITUIDO, ALQUILENO OPCIONALMENTE SUSTITUIDO, HETEROARILO OPCIONALMENTE SUSTITUIDO, ACILO, AMINOCARBONILO, ENTRE OTROS; R7 ES H O ALQUILO C1-6 OPCIONALMENETE SUSTITUIDO. SON COMPUESTOS PREFERIDOS: 2,6-DICLORO-4-(2-METOXIETOXI)-N-(4-(2-OXO-1,2-DIHIDROPIRIDIN-4-IL)BENCIL)BENZAMIDA; 2,6-DICLORO-N-[4-(2-OXO-1,2-DIHIDRO-PIRIDIN-4-IL)BENCIL]-BENZAMIDA; ENTRE OTROS. REFERIDO ADEMAS A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ALDEHIDO DESHIDROGENASA (ALDH-2) MITOCONDRIAL HUMANA, SIENDO UTILES PARA EL TRATAMIENTO DE LA DEPENDENCIA A DROGAS DE ADICCION EN MAMIFEROS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161503923P | 2011-07-01 | 2011-07-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20141067A1 true PE20141067A1 (es) | 2014-09-05 |
Family
ID=46513858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013002811A PE20141067A1 (es) | 2011-07-01 | 2012-06-29 | Compuestos para el tratamiento de la adiccion |
Country Status (32)
| Country | Link |
|---|---|
| US (6) | US8558001B2 (es) |
| EP (2) | EP2726460B1 (es) |
| JP (1) | JP5943998B2 (es) |
| KR (2) | KR101664915B1 (es) |
| CN (1) | CN103635460B (es) |
| AP (1) | AP3544A (es) |
| AR (1) | AR086792A1 (es) |
| AU (1) | AU2012279332B2 (es) |
| BR (1) | BR112014000033A2 (es) |
| CA (1) | CA2840763C (es) |
| CL (1) | CL2013003597A1 (es) |
| CO (1) | CO6821964A2 (es) |
| CR (1) | CR20130659A (es) |
| DK (1) | DK2993170T3 (es) |
| EA (1) | EA025573B1 (es) |
| EC (1) | ECSP13013087A (es) |
| ES (2) | ES2553829T3 (es) |
| HK (2) | HK1197236A1 (es) |
| IL (1) | IL230657B (es) |
| MA (1) | MA35404B1 (es) |
| MD (1) | MD4436B1 (es) |
| MX (1) | MX337611B (es) |
| PE (1) | PE20141067A1 (es) |
| PL (1) | PL2726460T3 (es) |
| PT (1) | PT2726460E (es) |
| SG (1) | SG10201605355RA (es) |
| SI (1) | SI2726460T1 (es) |
| TW (1) | TWI567061B (es) |
| UA (1) | UA109199C2 (es) |
| UY (1) | UY34165A (es) |
| WO (1) | WO2013006400A1 (es) |
| ZA (1) | ZA201308977B (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10457659B2 (en) | 2011-04-29 | 2019-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for increasing proliferation of adult salivary stem cells |
| EP2707361B1 (en) | 2011-05-10 | 2017-08-23 | Gilead Sciences, Inc. | Fused heterocyclic compounds as sodium channel modulators |
| TWI567061B (zh) | 2011-07-01 | 2017-01-21 | 吉李德科學股份有限公司 | 用於治療成癮之化合物 |
| TWI549944B (zh) | 2011-07-01 | 2016-09-21 | 吉李德科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| NO3175985T3 (es) | 2011-07-01 | 2018-04-28 | ||
| WO2014160185A2 (en) * | 2013-03-14 | 2014-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof |
| EP3459958A1 (en) * | 2013-12-13 | 2019-03-27 | Vertex Pharmaceuticals Incorporated | Process and intermediates for preparing prodrugs of pyridone amides useful as modulators of sodium channels |
| US10077669B2 (en) | 2014-11-26 | 2018-09-18 | United Technologies Corporation | Non-metallic engine case inlet compression seal for a gas turbine engine |
| US10289971B2 (en) | 2015-02-13 | 2019-05-14 | Atlassian Pty Ltd | Issue and trigger rebalancing in a ranked issue management system |
| PL3500572T3 (pl) | 2016-08-19 | 2023-02-06 | The University Of Bristol | Pochodne cytyzyny w leczeniu uzależnienia |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| AU2018352215A1 (en) * | 2017-10-16 | 2020-04-16 | Amygdala Neurosciences, Inc. | Combination therapy for preventing addiction |
| WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| TWI712412B (zh) | 2018-04-19 | 2020-12-11 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| DK3793565T3 (en) | 2018-05-14 | 2022-03-07 | Gilead Sciences Inc | Mcl-1-inhibitorer |
| KR20230159715A (ko) | 2018-07-13 | 2023-11-21 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| EP3829562A1 (en) * | 2018-07-27 | 2021-06-09 | Amygdala Neurosciences, Inc. | Combination therapy for nicotine addiction |
| WO2020076974A1 (en) * | 2018-10-12 | 2020-04-16 | Amygdala Neurosciences, Inc. | Addiction treatment of an alcohol-consuming patient population |
| CN112955435A (zh) | 2018-10-24 | 2021-06-11 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| US20230399299A1 (en) | 2022-06-14 | 2023-12-14 | Amygdala Neurosciences, Inc. | Aldh-2 inhibitor compounds and methods of use |
| WO2023244574A1 (en) | 2022-06-14 | 2023-12-21 | Amygdala Neurosciences, Inc. | Aldh-2 inhibitor compounds and methods of use |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| US5204369A (en) | 1991-07-01 | 1993-04-20 | The Endowment For Research In Human Biology | Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse |
| CA2334830A1 (en) | 1998-05-12 | 1999-11-18 | The Endowment For Research In Human Biology, Inc. | Methods and assays useful in the treatment of alcohol dependence or alcohol abuse |
| CN1671373A (zh) | 2002-06-27 | 2005-09-21 | 人类生物研究基金公司 | 用于抑制aldh的化合物 |
| JP2004182657A (ja) * | 2002-12-04 | 2004-07-02 | Eisai Co Ltd | Ｈｄｌレベル上昇促進剤 |
| US20080004260A1 (en) * | 2006-06-29 | 2008-01-03 | Transcept Pharmaceuticals, Inc. | Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions |
| US20080207610A1 (en) | 2006-07-27 | 2008-08-28 | Jeff Zablocki | Aldh-2 inhibitors in the treatment of addiction |
| EP2046769A2 (en) * | 2006-07-27 | 2009-04-15 | Cv Therapeutics, Inc. | Aldh-2 inhibitors in the treatment of addiction |
| US8158810B2 (en) | 2006-07-27 | 2012-04-17 | Gilead Sciences, Inc. | ALDH-2 inhibitors in the treatment of addiction |
| CN101669030B (zh) | 2007-03-08 | 2016-01-13 | 小利兰·斯坦福大学托管委员会 | 线粒体醛脱氢酶2调节剂和其使用方法 |
| WO2009094028A1 (en) | 2008-01-24 | 2009-07-30 | Cv Therapeutics, Inc. | Aldh-2 inhibitors in the treatment of addiction |
| EP2300461B1 (en) | 2008-05-01 | 2013-04-17 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| JP2012502048A (ja) | 2008-09-08 | 2012-01-26 | ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | アルデヒドデヒドロゲナーゼ活性のモジュレーターおよびその使用方法 |
| US8389522B2 (en) * | 2008-10-28 | 2013-03-05 | The Board Of Trustees Of The Leland Stanford Junior University | Modulators of aldehyde dehydrogenase and methods of use thereof |
| UY33469A (es) * | 2010-06-29 | 2012-01-31 | Irm Llc Y Novartis Ag | Composiciones y metodos para modular la via de señalizacion de wnt |
| TWI567061B (zh) | 2011-07-01 | 2017-01-21 | 吉李德科學股份有限公司 | 用於治療成癮之化合物 |
-
2012
- 2012-06-26 TW TW101122794A patent/TWI567061B/zh active
- 2012-06-27 UY UY0001034165A patent/UY34165A/es not_active Application Discontinuation
- 2012-06-28 AR ARP120102331A patent/AR086792A1/es not_active Application Discontinuation
- 2012-06-29 DK DK15184883.5T patent/DK2993170T3/da active
- 2012-06-29 ES ES12735394.4T patent/ES2553829T3/es active Active
- 2012-06-29 MD MDA20140009A patent/MD4436B1/ro not_active IP Right Cessation
- 2012-06-29 WO PCT/US2012/044809 patent/WO2013006400A1/en active Application Filing
- 2012-06-29 ES ES15184883.5T patent/ES2656716T3/es active Active
- 2012-06-29 PE PE2013002811A patent/PE20141067A1/es not_active Application Discontinuation
- 2012-06-29 AP AP2013007282A patent/AP3544A/xx active
- 2012-06-29 PL PL12735394T patent/PL2726460T3/pl unknown
- 2012-06-29 BR BR112014000033A patent/BR112014000033A2/pt active Search and Examination
- 2012-06-29 PT PT127353944T patent/PT2726460E/pt unknown
- 2012-06-29 CN CN201280032944.6A patent/CN103635460B/zh not_active Expired - Fee Related
- 2012-06-29 SI SI201230340T patent/SI2726460T1/sl unknown
- 2012-06-29 US US13/537,536 patent/US8558001B2/en active Active
- 2012-06-29 CA CA2840763A patent/CA2840763C/en active Active
- 2012-06-29 EP EP12735394.4A patent/EP2726460B1/en active Active
- 2012-06-29 SG SG10201605355RA patent/SG10201605355RA/en unknown
- 2012-06-29 KR KR1020147002302A patent/KR101664915B1/ko active IP Right Grant
- 2012-06-29 MX MX2013014938A patent/MX337611B/es active IP Right Grant
- 2012-06-29 AU AU2012279332A patent/AU2012279332B2/en not_active Ceased
- 2012-06-29 EA EA201391635A patent/EA025573B1/ru not_active IP Right Cessation
- 2012-06-29 EP EP15184883.5A patent/EP2993170B1/en active Active
- 2012-06-29 JP JP2014519122A patent/JP5943998B2/ja active Active
- 2012-06-29 UA UAA201314148A patent/UA109199C2/ru unknown
- 2012-06-29 KR KR1020167023967A patent/KR20160106207A/ko not_active Application Discontinuation
-
2013
- 2013-03-08 US US13/791,422 patent/US8575353B2/en active Active
- 2013-08-13 US US13/966,029 patent/US9000015B2/en active Active
- 2013-11-28 ZA ZA2013/08977A patent/ZA201308977B/en unknown
- 2013-12-13 CR CR20130659A patent/CR20130659A/es unknown
- 2013-12-16 CL CL2013003597A patent/CL2013003597A1/es unknown
- 2013-12-18 CO CO13295408A patent/CO6821964A2/es active IP Right Grant
- 2013-12-18 EC ECSP13013087 patent/ECSP13013087A/es unknown
- 2013-12-30 MA MA36629A patent/MA35404B1/fr unknown
-
2014
- 2014-01-26 IL IL230657A patent/IL230657B/en active IP Right Grant
- 2014-10-27 HK HK14110733A patent/HK1197236A1/xx not_active IP Right Cessation
-
2015
- 2015-03-16 US US14/659,042 patent/US9610299B2/en active Active
-
2016
- 2016-05-12 HK HK16105461.1A patent/HK1217487A1/zh not_active IP Right Cessation
-
2017
- 2017-03-31 US US15/476,569 patent/US9987295B2/en active Active
-
2018
- 2018-05-08 US US15/974,171 patent/US10507215B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20141067A1 (es) | Compuestos para el tratamiento de la adiccion | |
| PE20170331A1 (es) | Derivados quinolina como inhibidores smo | |
| PE20161416A1 (es) | Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1 | |
| PE20141064A1 (es) | Compuestos de ester boronato y composciones farmaceuticas de los mismos | |
| PE20170004A1 (es) | Inhibidores de biaril cinasa | |
| BR112014015363A8 (pt) | derivados de ácido alfa-amino borônico, inibidores de imunoproteassoma seletivos | |
| AR072490A1 (es) | 1,2,5- oxadiazoles como inhibidores de indolamina 2,3 dioxigenasa | |
| PE20151602A1 (es) | SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR B(beta)2 ADRENERGICO ASI COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARINICO M3 | |
| PE20160863A1 (es) | Proceso para la sintesis de un inhibidor de indolamina 2,3-dioxigenasa | |
| PE20170705A1 (es) | Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion) | |
| CU20110217A7 (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
| AR057109A1 (es) | Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis | |
| PE20091002A1 (es) | Analogos dipeptidos como inhibidores del factor de coagulacion | |
| AR084174A1 (es) | Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica | |
| PE20120171A1 (es) | Sales de adicion de aminas que contienen grupos hidroxilo y/o carboxilicos con derivados de acidos aminonicotinico como inhibidores de dhodh | |
| PE20141167A1 (es) | Piridopirazinas sustituidas como inhibidores novedosos de ptk | |
| PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
| AR084144A1 (es) | Compuestos y metodos para restaurar la piel | |
| AR087995A1 (es) | Derivados de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n-(4-fluorofenil)ciclopropan-1,1-dicarboxamida | |
| PE20151666A1 (es) | Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep | |
| BR112013029999A2 (pt) | derivados de tiazol | |
| PE20141679A1 (es) | Derivados de bencil sulfonamida utiles como inhibidores de mogat-2 | |
| EA201300436A8 (ru) | Совместные кристаллы и соли ингибиторов ccr3 | |
| PE20142244A1 (es) | Inhibidores de pirazolopirimidinilo de enzima activadora de ubiquitina | |
| EA201391524A1 (ru) | Производные гликозида и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |